United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

27 Jul 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for GALT.OQ


Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)


Beta: 1.39
Market Cap(Mil.): $45.21
Shares Outstanding(Mil.): 28.98
Dividend: --
Yield (%): --


  GALT.OQ Industry Sector
P/E (TTM): -- 42.42 37.52
EPS (TTM): -0.90 -- --
ROI: -91.25 -9.34 14.48
ROE: -138.94 -9.70 15.65

BRIEF-Galectin Therapeutics reports positive mid-stage data on psoriasis drug

* Two adverse events were noted, one infiltration of intravenous catheter & one headache during infusion; were mild & transient

May 16 2016

BRIEF-Galectin Therapeutics completes enrollment in mid stage trial for NASH drug

* Completion of enrollment in phase 2 clinical trial with GR-MD-02 in patients with NASH with advanced fibrosis

May 11 2016

BRIEF-Galectin Therapeutics Inc qtrly loss per share $0.24

* Believes it has sufficient cash to fund currently planned operations, research and development activities through march 31, 2017

May 10 2016

BRIEF-Galectin Therapeutics reports Q1 loss $0.24/shr

* Galectin Therapeutics reports first quarter 2016 financial results and provides business update

May 10 2016


Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
Provider : Pechala's Reports
Provider : Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.